Before the incretin drug class proved its potential, the notion that obesity could be treated with a pill or injection was almost science fiction. Decades of research had yielded approaches with meagre efficacy or unacceptable safety, banishing the few medicines that made it to market to commercial obscurity.
The next burning question is; how large could this market become?
The hype around obesity is significant – but is it justified? There are still questions to address:
- How long patients might stay on these drugs?
- Can we afford to pay for them? But given the potential benefits – can we afford not to?
- Who else is poised to enter the market to take on Novo and Lilly?
- What are the mechanisms that will drive the next wave of these drugs?
We’ve dug into Evaluate Omnium’s wealth of forecast data, to investigate the future of this market.
